SelectMDx™ helps identify patients at increased risk for aggressive disease, thereby aiding in the selection of men for prostate biopsy.

**Science:**
A two mRNA gene reverse transcription PCR assay that measures the urinary mRNA levels of DLX1 and HOXC6 biomarkers to aid in patient selection for prostate biopsy. A logistic regression model combining the two genes mRNA levels with established clinical risk factors is used to estimate the likelihood of detection GS ≥7 prostate cancer upon biopsy, in addition to the likelihood of no cancer or GS ≤6 disease.

**Results:**
- Increased risk for GS ≥7 prostate cancer
- Very low risk for GS ≥7 prostate cancer. 98% NPV for GS ≥7 disease and 99% NPV for GS ≥8 prostate cancer

MDxHealth
- 866-259-5644
- Mdxhealth.com

www.prostatemarkers.org
www.prostateconditions.org